Which Uterotonic Is Better to Prevent the Postpartum Hemorrhage? Latest News in Terms of Clinical Efficacy, Side Effects, and Contraindications: A Systematic Review

被引：45

作者：

Gizzo, Salvatore ^{[1
]}

Patrelli, Tito Silvio ^{[2
]}

Di Gangi, Stefania ^{[1
]}

Carrozzini, Monica ^{[1
]}

Saccardi, Carlo ^{[1
]}

Zambon, Alessandra ^{[1
]}

Bertocco, Anna ^{[1
]}

Fagherazzi, Simone ^{[1
]}

D'Antona, Donato ^{[1
]}

Nardelli, Giovanni Battista ^{[1
]}

机构：

[1] Univ Padua, Dept Woman & Child Hlth, I-35128 Padua, Italy

[2] Univ Parma, Dept Obstet Gynecol & Neonatol Sci, I-43100 Parma, Italy

来源：

REPRODUCTIVE SCIENCES | 2013年 / 20卷 / 09期

关键词：

postpartum hemorrhage; blood loss prevention; uterotonic drugs; active management; third stage of labor;

D O I：

10.1177/1933719112468951

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

Background: Postpartum hemorrhage (PPH) is a potentially fatal complication of vaginal and cesarean deliveries. The active management of the third stage of labor provides administration of prophylactic uterotonic drugs just before or immediately after delivery, since they reduce the risk of PPH by 60%. Objective: Overview on all available uterotonics for PPH prevention to clarify indications and contraindications in choice among drugs. Search Strategy: Systematic review of the literature. Main Results: Oxytocin is the first choice for PPH prophylaxis. Ergot alkaloids, syntometrine, and prostaglandins are second-line uterotonic agents. Misoprostol is not effective as oxytocin but it may be used when the latter is not available. Carbetocin should be used instead of continuous oxytocin infusion in elective cesarean sections for PPH prevention and to decrease the need for therapeutic uterotonics. Conclusions: Prophylactic oxytocics should be offered routinely in the third stage of labor in all women. The prophylactic use of uterotonics should be individualized.

引用

页码：1011 / 1019

页数：9

共 48 条

[1]

Leduc D., Senikas V., Lalonde A.B., Clinical Practice Obstetrics Committee

[2]

Society of Obstetricians and Gynaecologists of Canada. Active management of the third stage of labour: Prevention and treatment of postpartum hemorrhage, J Obstet Gynaecol Can, 31, 10, pp. 980-993, (2009)

[3]

Carroli G., Cuesta C., Abalos E., Gulmezoglu A.M., Epidemiology of postpartum haemorrhage: A systematic review, Best Pract Res Clin Obstet Gynaecol, 22, 6, pp. 999-1012, (2008)

[4]

Begley C.M., Gyte G.M., Devane D., McGuire W., Weeks A., Active versus expectant management for women in the third stage of labour, Cochrane Database Syst Rev, 11, (2011)

[5]

Thomas J., Callwood A., Paranjothy S., National Sentinel Caesarean Section Audit: Update, Pract Midwife, 3, 11, (2000)

[6]

Oladapo O.T., Fawole B., Blum J., Abalos E., Advance misoprostol distribution for preventing and treating postpartum haemorrhage, Cochrane Database Syst Rev, 2, (2012)

[7]

ACOG Practice Bulletin: Clinical Management Guidelines for Obstetrician-Gynecologists Number 76, October 2006: Postpartum hemorrhage, Obstet Gynecol, 108, 4, pp. 1039-1047, (2006)

[8]

Jansen A.J., Van Rhenen D.J., Steegers E.A., Duvekot J.J., Postpartum hemorrhage and transfusion of blood and blood components, Obstet Gynecol Surv, 60, 10, pp. 663-671, (2005)

[9]

Combs C.A., Murphy E.L., Laros R.K., Factors associated with postpartum hemorrhage with vaginal birth, Obstet Gynecol, 77, 1, pp. 69-76, (1991)

[10]

Prendiville W., Elbourne D., Chalmers I., The effects of routine oxytocic administration in the management of the third stage of labour: An overview of the evidence from controlled trials, Br J Obstet Gynaecol, 95, 1, pp. 3-16, (1988)

← 1 2 3 4 5 →